
Abbott has announced the initiation of the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis (AS). The first enrolment in the VOYAGER CE study occurred at Macquarie University in Sydney, Australia, led by Stephen Worthley.
The prospective, single-arm, premarket study will enrol up to 300 patients in Europe and Australia with symptomatic severe AS caused by severe calcium buildup in the aortic valve. The study will be the basis to seek approval for use in Europe and Australia.
“TAVI has transformed the treatment of severe aortic stenosis, but physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients,” said Didier Tchétché, director of the structural heart disease department, Clinique Pasteur, Toulouse, France, and co-principal investigator of VOYAGER CE. “Encantor’s balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence.”
The investigational Encantor system works by crimping the new heart valve on a deflated surgical balloon. The balloon with the mounted valve is then inserted into the body and guided through a catheter in an artery in the groin to the heart. Once properly positioned inside the diseased aortic valve, software-guided deployment helps customise expansion of the valve to the patient’s unique anatomy for a more precise fit, Abbott says in a press release. Once the new valve is in place, it takes over the function of the patient’s damaged native valve. The balloon is then deflated and removed from the body.
“Our ambition is to give physicians the right technology for each patient,” Sandra Lesenfants, senior vice president of Abbott’s structural heart business, was quoted as saying in a press release. “Our investigational Encantor system complements our Navitor self-expanding platform with a balloon-expandable option designed around physician insights, precise deployment and procedural ease of use. Advancing VOYAGER CE brings us another step closer to offering physicians a broader portfolio of structural heart solutions.”
Abbott plans to initiate a pivotal trial in the USA in the coming months.











